<html>

        <head>
        <link href="../style1.css" rel="stylesheet" type="text/css">
        </head>
        <table border = 1>
        <tr>
        <th>PubMedID</th>
        <th>Sentence</th>
        <th>First Gene</th>
        <th>Second Gene</th>
        <th>Interaction</th>
        </tr>
        <body>
<tr class = "cellcolor">
<td>24294538</td>
<td>Finally, a family-based breast cancer study of the BRCA1 and BRCA2 genes is used to illustrate the method.</td>
<td>BRCA1</td>
<td>BRCA2</td>
<td>None</td>
</tr>
<tr class = "cellcolor">
<td>24292448</td>
<td>Background:The BRCA1 and BRCA2 genes confer increased susceptibility to breast and ovarian cancer and to a spectrum of other cancers</td>
<td>BRCA1</td>
<td>BRCA2</td>
<td>None</td>
</tr>
<tr class = "cellcolor">
<td>24289560</td>
<td>We aimed at determining whether any association exists between single nucleotide polymorphisms in breast cancer associated gene 1 (BRCA1) and breast cancer associated gene 2 (BRCA2) and the risk of breast cancer</td>
<td>BRCA1</td>
<td>BRCA2</td>
<td>None</td>
</tr>
<tr class = "cellcolor">
<td>24289560</td>
<td>TaqMan based Real Time Polymerase chain reaction genotyping assays were used to determine the frequency  of single nucleotide polymorphisms in BRCA1 (rs799917) and BRCA2 (rs144848) in a  group of 100 breast cancer patients and unaffected age matched controls of Saudi  Arabian origin</td>
<td>BRCA1</td>
<td>BRCA2</td>
<td>None</td>
</tr>
<tr class = "cellcolor">
<td>24289560</td>
<td>The present data revealed that neither BRCA1 nor the BRCA2 studied variant show any significant association with the disease</td>
<td>BRCA1</td>
<td>BRCA2</td>
<td>None</td>
</tr>
<tr class = "cellcolor">
<td>24285858</td>
<td>BACKGROUND: BRCA1 or BRCA2 mutations confer increased risks of breast and ovarian cancer, but risks have been found to vary across studies and populations</td>
<td>BRCA1</td>
<td>BRCA2</td>
<td>None</td>
</tr>
<tr class = "cellcolor">
<td>24285858</td>
<td>METHODS: We ascertained pedigree data of 582 BRCA1 and 176 BRCA2 families and studied the variation in breast and ovarian cancer risks using a modified segregation analysis model</td>
<td>BRCA1</td>
<td>BRCA2</td>
<td>None</td>
</tr>
<tr class = "cellcolor">
<td>24285729</td>
<td>BRCA1, BRCA2 and PALB2 are key players in cellular tolerance to chemotherapeutic  agents including camptothecin, cisplatin and poly[ADP ribose]polymerase inhibitor</td>
<td>BRCA1</td>
<td>BRCA2</td>
<td>None</td>
</tr>
